Loading...

SENS: Future Commercial Rollout Will Drive Diabetes Monitoring Adoption

Published
28 Mar 25
Updated
03 Nov 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
3.6%
7D
-1.1%

Author's Valuation

US$25.3375.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 03 Nov 25

Fair value Decreased 11%

Analysts have revised their price target for Senseonics Holdings downward from $28.60 to $25.33 per share, citing expected financial impacts from the company's assumption of commercial operations. This is balanced by continued optimism over the Eversense 365 system's market potential.

Shared on 20 Oct 25

Fair value Increased 2k%

Analysts have significantly increased their price target for Senseonics Holdings from $1.43 to $28.60. They cite growing confidence in the company's expanding product offerings and anticipated demand for its Eversense 365 sensor system.

Shared on 08 Aug 25

Fair value Decreased 7.74%

The downward revision in Senseonics Holdings’ price target reflects a combination of lowered future earnings multiples and a higher discount rate, resulting in the consensus fair value estimate declining from $1.55 to $1.41. What's in the News Senseonics Holdings completed a $50 million follow-on equity offering, issuing 100 million common shares at $0.50 per share with a $0.03 discount.

Shared on 01 May 25

Shared on 24 Apr 25

Fair value Decreased 13%

Shared on 17 Apr 25

Fair value Increased 5.95%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 8.39%

AnalystConsensusTarget has decreased revenue growth from 53.7% to 38.3%, increased future PE multiple from 167.2x to 202.9x and decreased shares outstanding growth rate from 0.2% to 0.1%.